| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028705141 |
| P356 | DOI | 10.1007/S11060-004-3550-9 |
| P698 | PubMed publication ID | 15925989 |
| P50 | author | Ryuya Yamanaka | Q38801940 |
| P2093 | author name string | Ryuichi Tanaka | |
| Naoki Yajima | |||
| Naoto Tsuchiya | |||
| Tsutomu Kobayashi | |||
| Junpei Honma | |||
| P2860 | cites work | In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites | Q28586653 |
| The dendritic cell system and its role in immunogenicity | Q29619870 | ||
| Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. | Q30463850 | ||
| Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. | Q32113039 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide | Q34765735 | ||
| Dendritic cell-based glioma immunotherapy (review). | Q35147825 | ||
| Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology | Q35470135 | ||
| Proliferating dendritic cell progenitors in human blood | Q36363279 | ||
| Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes | Q36364266 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity | Q36366130 | ||
| Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo | Q36367135 | ||
| Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial | Q36671200 | ||
| Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system | Q37340361 | ||
| Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma | Q40900120 | ||
| A Simple and Reliable Method for Screening Retroviral Producer Clones Without Selectable Markers | Q41102466 | ||
| Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens | Q41668632 | ||
| Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors | Q42029476 | ||
| Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. | Q42627953 | ||
| Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma | Q43757209 | ||
| Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor | Q43836464 | ||
| Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration | Q46720423 | ||
| A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. | Q48603942 | ||
| Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. | Q54960119 | ||
| Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. | Q55473959 | ||
| Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth | Q72057620 | ||
| HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer | Q72682038 | ||
| Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production | Q72686394 | ||
| Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts | Q73209043 | ||
| P433 | issue | 2 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 107-113 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma | |
| P478 | volume | 72 |
| Q42910288 | Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells? |
| Q38673161 | Cellular immunotherapy of cancer: an overview and future directions |
| Q35843507 | Challenges and future perspectives of T cell immunotherapy in cancer |
| Q40052359 | Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. |
| Q38094808 | Current and future directions for Phase II trials in high-grade glioma |
| Q24641823 | Dendritic cell vaccines for brain tumors |
| Q37945301 | Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? |
| Q34721575 | Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. |
| Q37517954 | Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas |
Search more.